US20010031244A1 - Pharmaceutical aerosol composition - Google Patents

Pharmaceutical aerosol composition Download PDF

Info

Publication number
US20010031244A1
US20010031244A1 US09/796,607 US79660701A US2001031244A1 US 20010031244 A1 US20010031244 A1 US 20010031244A1 US 79660701 A US79660701 A US 79660701A US 2001031244 A1 US2001031244 A1 US 2001031244A1
Authority
US
United States
Prior art keywords
composition
low volatility
aerosol
mmad
volatility component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/796,607
Inventor
David Lewis
Davis Ganderton
Brian Meakin
Paolo Ventura
Gaetano Brambilla
Raffaella Garzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9712434A priority Critical patent/GB2326334A/en
Priority to GB9712434.1 priority
Priority to US14766999A priority
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to US09/796,607 priority patent/US20010031244A1/en
Publication of US20010031244A1 publication Critical patent/US20010031244A1/en
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAMBILLA, GAETANO, GANDERTON, DAVIS, GARZIA, RAFFAELLA, LEWIS, DAVID, MEAKIN, BRIAN, VENTURA, PAOLO
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/958Drug, bio-affecting and body treating compositions for smoking or inhaling

Abstract

A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.

Description

  • The invention relates to aerosol compositions for pharmaceutical use. In particular, this invention relates to aerosol compositions for use in pressurised metered dose inhalers (MDI). The invention also relates to the use of certain components in aerosol compositions, a method for their preparation and to their use for the administration of active material by inhalation. [0001]
  • Inhalers are well known devices for administering pharmaceutical products to the respiratory tract by inhalation. [0002]
  • Active materials commonly delivered by inhalation include bronchodilators such as β2 agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material. [0003]
  • There are a number of types of inhaler currently available. The most widely used type is a pressurised metered dose inhaler (MDI) which uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. Formulations used in MDIs (aerosol formulations) generally comprise the active material, one or more liquefied propellants and a surfactant or a solvent. [0004]
  • For many years the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CC1[0005] 3F (Freon 11 or CFC-11), CC12F (Freon 12 or CFC-12), and CC12-CC1F2 (Freon 114 or CFC-114). Chlorofluorocarbons have properties particularly suitable for use in aerosols, including high vapour pressure which generates clouds of droplets of a suitable particle size from the inhaler.
  • Recently, the chlorofluorocarbon (CFC) propellants such as Freon 11 and Freon 12 have been implicated in the destruction of the ozone layer and their production is being phased out. [0006]
  • In 1987, under the auspices of the United Nations Environmental Programme, the Montreal Protocol on Substances that Deplete the Ozone Layer was developed calling for the progressive reduction in CFC use until their elimination. [0007]
  • The aerosol pharmaceutical products for the treatment of asthma and bronchopulmonary diseases are agreed to be essential and enjoy a temporary exemption. However it is believed that the medical use of CFCs will be discontinued in the near future. The ozone-destroying potential of CFCs is proportional to the chlorine content. [0008]
  • Hydrofluoroalkanes [(HFAs) known also as hydro-fluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs. [0009]
  • HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems are disclosed in several patent applications. [0010]
  • Many of these applications, in which HFAs are used as propellant, propose the addition of one or more of adjuvants including compounds acting as cosolvents, surface active agents including fluorinated and non-fluorinated surfactants, dispersing agents including alkylpolyethoxylates and stabilizers. [0011]
  • Cosolvents which may be used in these formulations include alcohols such as ethanol and polyols such as propylene glycol. [0012]
  • Medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777. EP 0372777 requires the use of HFA 134a as a propellant in combination with both a surfactant and an adjuvant having higher polarity than the propellant. [0013]
  • For aerosol suspension compositions, a surfactant is often added to improve the physical stability of the suspension. EP 0372777 states that the presence of surfactant assists in the preparation of stable, homogeneous suspensions and may also assist in the preparation of stable solution formulations. [0014]
  • Surfactants also lubricate the valve components in the inhaler device. [0015]
  • The use of propylene glycol as a solvent having a higher polarity than the propellant in HFA pressurized metered dose inhalers formulations has been mentioned in several other patent applications and for example in: [0016]
  • EP 504112 relates to a pharmaceutical aerosol formulation free from CFCs containing a propellant (hydrocarbon, HFA or a mixture), one or more pharmaceutical active ingredients, a non-ionic surfactant and optionally other conventional pharmaceutical auxiliaries suitable for aerosol formulations comprising solvents having a higher polarity than the propellant, other non-ionic surfactants as valve lubricants, vegetable oils, phospholipids, taste masking agents. [0017]
  • DE 4123663 describes a medical aerosol composition containing a dispersion or suspension of an active agent in association with a compound with surface-active or lipophilic properties, heptafluoropropane as propellant and an alcohol such as ethanol and/or propylene glycol. [0018]
  • U.S. Pat. No. 5,534,242 describes an aerosol-dispensable pharmaceutical composition comprising lidocaine base and a vasoconstrictor dissolved in an HFA propellant and optionally an organic solvent. [0019]
  • Other applications propose the addition of dispersing agents to the composition. U.S. Pat. No. 5,502,076 concerns compositions used in inhalation aerosols comprising an HFA, leukotriene antagonists and dispersing agent comprising 3C-linked triesters, vitamin E acetate, glycerin, t-BuOH, or transesterified oil/polyethylene glycol. [0020]
  • EP 384371, describes a propellant for an aerosol, comprising pressure-liquefied HFA 227 in a mixture with pressure-liquefied propane and/or n-butane and/or iso-butane and/or dimethyl ether and/or 1,1-difluoroethane. The document also discloses foam formulations (shaving and shower foams) containing glycerol as additive. [0021]
  • The effectiveness of an aerosol device, for example an MDI, is a function of the dose deposited at the appropriate site in the lungs. Deposition is affected by several factors, of which one of the most important is the aerodynamic particle size. Solid particles and/or droplets in an aerosol formulation can be characterized by their mass median aerodynamic diameter (MMAD, the diameter around which the mass aerodynamic diameters are distributed equally). [0022]
  • Particle deposition in the lung depends largely upon three physical mechanisms: (1) impaction, a function of particle inertia; (2) sedimentation due to gravity; and (3) diffusion resulting from Brownian motion of fine, submicrometer (<1 μm) particles. The mass of the particles determines which of the three main mechanisms predominates. [0023]
  • The effective aerodynamic diameter is a function of the size, shape and density of the particles and will affect the magnitude of forces acting on them. For example, while inertial and gravitational effects increase with increasing particle size and particle density, the displacements produced by diffusion decrease. In practice, diffusion plays little part in deposition from pharmaceutical aerosols. Impaction and sedimentation can be assessed from a measurement of the mass median diameter (MMAD) which determines the displacement across streamlines under the influence of inertia and gravity, respectively. [0024]
  • Aerosol particles of equivalent MMAD and GSD (Geometric Standard Deviation) have similar deposition in the lung irrespective of their composition. The GSD is a measure of the variability of the aerodynamic particle diameters. [0025]
  • For inhalation therapy there is a preference for aerosols in which the particles for inhalation have a diameter of about 0.8 to 5 μm. Particles which are larger than 5 μm in diameter are primarily deposited by inertial impaction in the oropharynx, particles 0.5 to 5 μm in diameter, influenced mainly by gravity, are ideal for deposition in the conducting airways, and particles 0.5 to 3 μm in diameter are desirable for aerosol delivery to the lung periphery. Particles smaller than 0.5 μm may be exhaled. [0026]
  • Respirable particles are generally considered to be those with aerodynamic diameters less than 5 μm. These particles, particularly those with a diameter of about 3 μm, are efficiently deposited in the lower respiratory tract by sedimentation. [0027]
  • It has been recently demonstrated in patients with mild and severe airflow obstruction that the particle size of choice for a β2 agonist or anticholinergic aerosol should be approximately 3 μm (Zaanen P et al. Int J Pharm 1994, 107:211-7; Int J Pharm 1995, 114:111-5; Thorax 1996, 51:977-980). [0028]
  • Besides the therapeutic purposes, the size of aerosol particles is important in respect to the side effects of the drugs. For example, it is well known that the oropharynx deposition of aerosol formulations of steroids can result in side effects such as candidiasis of mouth and throat. [0029]
  • On the other hand a higher systemic exposure to the aerosol particles due to deep lung penetration can enhance the undesired systemic effects of the drugs. For example, the systemic exposure to steroids can produce side effects on bone metabolism and growth. [0030]
  • It has been reported that the particle size characteristics of HFA aerosol formulations of the state of the art are often very different from the products to be replaced. [0031]
  • EP 0553298 describes an aerosol formulation comprising: a therapeutically effective amount of beclomethasone 17,21 dipropionate (BDP); a propellant comprising a hydrofluorocarbon selected from the group consisting of HFA 134a, HFA 227, and a mixture thereof, and ethanol in an amount effective to solubilize the beclomethasone 17,21 dipropionate in the propellant. The formulation is further characterized in that substantially all of the beclomethasone 17,21 dipropionate is dissolved in the formulation and that the formulation contains no more than 0.0005% by weight of any surfactant. [0032]
  • It has been reported in literature that these new formulations of beclomethasone dipropionate (BDP) as a solution in HFA 134a deliver a particle size distribution with a MMAD of 1.1 μm. This means that the peripheral pulmonary deposition of very small particles increases and submicronic particles can easily be directly absorbed from the alveoli into the bloodstream. The rate and extent of systemic absorption is significantly increased and as a consequence undesired effects for example certain side effects can increase. A relatively large fraction of the dose is exhaled. The implications of this for clinical efficacy and toxic effects are great. They arise because the principles of formulation using HFAs may modify the physical form of the respired cloud. [0033]
  • According to the invention there is provided a composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. [0034]
  • The nature and concentration of the low volatility component can be chosen to influence, for example, the size and/or the density of the particle, both of which affect the MMAD. [0035]
  • It is an object of the invention to provide an aerosol formulation which avoids or mitigates the problems indicated above and in particular provides an aerosol composition including HFA as propellant having similar size characteristics to the CFC compositions which they replace. That would help to provide an MDI having HFAs as propellant which was pharmaceutically and clinically equivalent to the MDIs which use CFCs. [0036]
  • Although most commonly applied to formulae in which the active agent(s) is in solution, the principle can also be applied to suspension formulae and to mixed formulae in which only one of the components is present in solution form. [0037]
  • The invention thus allows the design of formulae using HFAs with similar particle size characteristics to those of the CFC formulations they replace. This allows development of products which are pharmaceutically and clinically equivalent to the CFC formulation. [0038]
  • Examples of low volatility components which may be included in the aerosol formulation to increase the MMAD of the aerosol particles include high density components, for example glycerol and propylene glycol, and low density compounds, for example oleic acid and certain vegetable oils. [0039]
  • Glycerol and propylene glycol have previously been investigated as additives in aqueous systems in relation to the nebulization of fluids by jet or ultrasonic nebulizers. The contents of propylene glycol or glycerol in these systems was very high (10-50% v/v). The results were equivocal. [0040]
  • Davis S S in Int J Pharm 1(2), 71-83, 1978 examined the aerosolization characteristics of two common nebulizers using a propylene glycol-water systems. The output of aerosol solution droplets passed through a max. at 30% vol./vol. propylene glycol; an increased output was parallelled by an increased particle size. [0041]
  • Davis SS et al. in Int J Pharm 1(2), 85-93, 1978 examined the output of aerosol droplets from a common nebulizer using a water-propylene glycol-ethanol system. [0042]
  • In general an increased alcohol content led to an increased total output from the nebulizer. However, much of this output was in the form of solvent vapour and only a modest increase in the output of therapeutically effective aerosol droplets was obtained. [0043]
  • Miller W C and Mason J W in J Aerosol Med 4(4), 293-4, 1991 used radioaerosol techniques to determine if adding propylene glycol would improve aerosol delivery of a jet nebulizer in spontaneously breathing normal human subjects. They found no significant differences in either deposition or penetration between saline control and a 20% propylene glycol solution. [0044]
  • McCallion et al. in Pharm Res 12(11), 1682-7, 1995 sought to evaluate in three types of jet nebulizer and two ultrasonic devices the influence on the aerosol's size and output characteristics of fluid systems containing water, ethanol, glycerol 10-50% (v/v) solutions, propylene glycol 10-50% (v/v) solutions and silicone fluids 200/0.65 cs-200/100 cs. The parameters considered were viscosity and surface tension. [0045]
  • Oleic acid has been used in aerosol formulations, in order to improve the physical stability of drug suspensions, as a dispersing agent useful in keeping the suspended particles from agglomerating. [0046]
  • It has now been surprisingly found that in solution formulations of the present application oleic acid can be used either as solubilizer and/or stabilizer of the active ingredient or a low volatility component. [0047]
  • When used as solubilizer/stabilizer the amount of oleic acid can be varied according to the concentration and the characteristics of the active material. When used as low volatility component the percentage concentration of oleic acid should be preferably no less than 0.5% w/w. [0048]
  • In general terms the low volatility component can be any compound, safe and compatible with the propellant system of the invention capable to influence either the size or the density of the aerosol particle so affecting the MMAD. [0049]
  • As it can be noticed from the results reported-in the tables, the influence of the low volatility component on the MMAD of the particles is correlated to its density. The higher the density of the low volatile ingredient, the higher the increase of the MMAD of the aerosol particles on actuation of the inhaler. [0050]
  • The applications concerning aerosol formulations using the new propellant systems disclosed in the known prior art seek to overcome problems of stability of the formulations. The present application seeks a solution both for the stability of the formulations and to the therapeutic problems associated with the new medicinal aerosols, as the presence in the formulation of a low volatility ingredient influences the most important factor affecting aerosol delivery to the lung: the aerodynamic mass of the particles. [0051]
  • It has surprisingly been found that by adding a low volatility component to the composition, the MMAD of the aerosol particles on actuation of the inhaler can be increased and thus the compositions may be formulated so that the aerodynamic particle size characteristics are similar to those for the CFC-propellant compositions. [0052]
  • Advantageously, the low volatility component has a vapour pressure at 25° C. not more than 0.1 kPa, preferably not more than 0.05 kPa. We have found that with the addition of components having such low vapour pressures, control of the MMAD may be obtained. [0053]
  • It is thought that the addition of the component having a low vapour pressure depresses the atomisable characteristics of the HFA propellant giving larger particles on actuation of the inhaler and after evaporation of the propellant. [0054]
  • The low vapour pressure of the low volatility component is to be contrasted with that of the cosolvent which preferably has a vapour pressure at 25° C. not less than 3 kPa, more preferably not less than 5 kPa. [0055]
  • The cosolvent has advantageously a higher polaritythan that of the propellant and the cosolvent is used to increase the solubility of the active material in the propellant. [0056]
  • Advantageously the cosolvent is an alcohol. The cosolvent is preferably ethanol. The cosolvent may include one or more materials. [0057]
  • The low volatility component may be a single material or a mixture of two or more materials. [0058]
  • We have found that glycols are particularly suitable for use as the low volatility component, especially propylene glycol, polyethylene glycol and glycerol. [0059]
  • Other particularly suitable materials are thought to include other alcohols and glycols, for example alkanols such as decanol (decyl alcohol), sugar alcohols including sorbitol, mannitol, lactitol and maltitol, glycofural (tetrahydro-furfurylalcohol) and dipropylene glycol. [0060]
  • It is also envisaged that various other materials may be suitable for use as the low volatility component including vegetable oils, organic acids for example saturated carboxylic acids including lauric acid, myristic acid and stearic acid; unsaturated carboxylic acids including sorbic acid, and especially oleic acid; saccharine, ascorbic acid, cyclamic acid, amino acids, or aspartame might be used. [0061]
  • The low volatility component may include esters for example ascorbyl palmitate and tocopherol; alkanes for example dodecane and octadecane; terpenes for example menthol, eucalyptol, limonene; sugars for example lactose, glucose, sucrose; polysaccharides for example ethyl cellulose, dextran; antioxidants for example butylated hydroxytoluene, butylated hydroxyanisole; polymeric materials for example polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrollidone; amines for example ethanolamine, diethanolamine, triethanolamine; steroids for example cholesterol, cholesterol esters. [0062]
  • The amount of low volatility component in the composition depends to some extent upon its density and the amount of active material and cosolvent in the composition. Advantageously, the composition includes not more than 20% by weight of the low volatility component. Preferably the composition includes not more than 10% by weight of the low volatility component. [0063]
  • On actuation of the inhaler, the propellant and the ethanol vaporise but because of the low vapour pressure of the low volatility component, that component generally will not. [0064]
  • It is thought that it is preferable for the composition to contain at least 0.2%, preferably at least 1% by weight of the low volatility component. The composition may contain between 1% and 2% by weight. [0065]
  • Most advantageously, the composition is such that, on actuation of the aerosol inhaler in use, the MMAD of the aerosol particles is not less than 2 μm. For some active materials the MMAD is preferably not less than 2.5 μm and for a few formulations, the preferred MMAD will be greater than 3 μm or even greater than 4 μm. As is indicated in the examples below, for one corresponding inhaler formulation using CFC propellants, the MMAD of the aerosol particles is approximately 2.8 μm (see Table 4 below). [0066]
  • Preferred HFA propellants are HFA 134a and HFA 227. The propellant may comprise a mixture of more than one component. [0067]
  • The composition may be in the form of a solution or a suspension or an ultrafine suspension or colloidal solution. The invention is particularly relevant where the composition is a solution but also relates to suspension, in particular those of small particle size. Preferably the composition is a solution. [0068]
  • In some cases a small quantity of water may be added to the composition to improve the solution of the active material and/or the low volatility component in the cosolvent. [0069]
  • The active material may be one or more of any biologically active material which could be administered by inhalation. Active materials commonly administered in that way include β2 agonists, for example salbutamol and its salts, steroids for example beclomethasone dipropionate or anti-cholergics for example ipratropium bromide. [0070]
  • The invention further provides use of a low volatility component in a composition for an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA) and a cosolvent, to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. [0071]
  • As indicated above, on actuation of the inhaler, the aerosol particles advantageously have an MMAD of not less than 2 μm, for many formulations more preferably not less than 2.5 μm. [0072]
  • As described above, the low volatility component advantageously has a vapour pressure at 25° C. not more than 0.1 kPa. [0073]
  • The invention also provides an inhaler containing the composition in accordance with the invention. [0074]
  • Also provided is a method of filling an aerosol inhaler with a composition, the method comprising filling the following components into the inhaler [0075]
  • (a) one or more active materials, [0076]
  • (b) one or more low volatility components, [0077]
  • (c) one or more cosolvents [0078]
  • followed by the addition of a propellant containing a hydrofluoroalkane (HFA). [0079]
  • The invention further provides aerosol particles emitted from an aerosol inhaler containing a composition, the composition comprising an active component, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and a low volatility component, wherein the mass median aerodynamic diameter (MMAD) of the aerosol particles is not less than 2 μm. [0080]
  • For some compositions, it is preferred that the MMAD of the particles is not less than 2.5 μm as indicated above. [0081]
  • The particles will usually be in the form of droplets.[0082]
  • Embodiments of the invention will now be described by way of example. [0083]
  • The aerosol compositions of the invention described below were prepared by the following method. The required components of a composition were added into a can in the following order: drug, non-volatile additive, absolute ethanol. After crimping of the valve on to the can, the propellant was added through the valve. The weight gain of the can after each component was added was recorded to allow the percentage, by weight, of each component in the formulation to be calculated. [0084]
  • The aerodynamic particle size distribution of each formulation was characterized using a Multistage Cascade Impactor according to the procedure described in the European Pharmacopoeia 2nd edition, 1995, part V.5.9.1. pages 15-17. In this specific case an Andersen Cascade Impactor (ACI) was used. Results represented were obtained from ten cumulative actuations of a formulation. Deposition of the drug on each ACI plate was determined by high pressure liquid chromatography. The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were calculated from plots of the cumulative percentage undersize of drug collected on each ACI plate (probit scale), against the upper cut off diameter for each respective ACI plate (log10 scale). The fine particle dose of each formulation was determined from the mass of drug collected on Stages 2 through to Filter (<5.8 μm) divided by the number of actuations per experiment. [0085]
  • Tables 1 and 2 show comparative examples indicating the characteristics of aerosol formulations containing HFA 134a, different beclomethasone dipropionate (BDP) (active material) amounts and different ethanol concentrations. The formulations do not contain a low volatility component. As can be seen, the MMAD is not substantially influenced by the ratio of cosolvent to propellant. [0086]
  • Increase of the concentration of the active ingredient gives a slight variation of MMAD which, in this case, is correlated with the BDP content. [0087]
  • For equal concentrations of BDP the content of ethanol and the addition up to 0.5% of water does not significantly affect the MMAD. [0088]
  • Table 3 compares the characteristics of a CFC ipratropium bromide (IPBr) standard formulation with HFA 134a, ethanol, ipratropium bromide solution formulations with a content of glycerol from 0 to 1%. [0089]
  • It can be seen that the MMAD of the formulation having the HFA as propellant is significantly lower than that for the conventional CFC formulation. [0090]
  • The MMAD of the HFA/ethanol-IPBr formulations is 1.2±1.9 or 1.3±0.1 μm depending on the content of ethanol (respectively 12.9±0.1% w/w and 25% w/w), in comparison with an MMAD of 2.8±0.1 μm of the CFC-IPBr formulation. [0091]
  • The addition of a low volatile additive such as glycerol increases the particle MMAD of the HFA solution formulations; the increase is correlated with the glycerol concentration. [0092]
  • In confirmation of the results of Tables 1 and 2 the MMAD is not substantially influenced by the ratio of cosolvent to propellant. [0093]
  • In other studies the effects of increasing concentrations of propylene glycol, glycerol and polyethylene glycol (PEG) in HFA 134a and ethanol beclomethasone dipropionate (BDP) formulations have been determined. [0094]
  • The % indicated for the components of the composition are % by weight unless indicated to the contrary. [0095]
  • The results are reported in Tables 4, 5, 6, 7 and 8. [0096]
  • The results show the direct relationship between the percentage of low volatile ingredient and particle MMAD. As we can notice there is a slight influence of the actuator orifice on the MMAD but the relationship between the concentration of low volatile ingredient and particle MMAD is maintained. These findings demonstrate that the addition of an established amount of low volatile additives in HFA formulations can increase the MMAD of the particles to values comparable to the MMAD of the previously known CFC formulations which the HFA formulations seek to replace. [0097]
  • Advantageously, the GSD is not significantly changed on addition of the low volatility component. In particular, for glycerol as the low volatility component, Tables 6 and 7 show that the GSD is not substantially changed by the addition of glycerol. Glycerol is a particularly preferred material for the low volatility component. [0098]
  • The increase in particle MMAD by the addition of an established amount of glycerol in HFA solution formulation has been observed also with flunisolide (Table 9), in the presence of a moderate concentration of a taste corrective such as menthol. [0099]
  • Analogous results have been obtained with salbutamol, as it can be noticed in Table 10. A small amount of oleic acid (0.3%) has been added to the formulation to improve the physical stability of the solution. In this concentration the oleic acid does not substantially modify the particle MMAD of the active material. [0100]
  • In Table 11 HFA 134a, ethanol 15.4±0.2%, BDP in combination with salbutamol formulations without and in presence of 1.2% of glycerol and with a content of oleic acid from 0 to 1.3% are compared. [0101]
  • The results show that: [0102]
  • a) the MMAD of the two active materials in solution combination without low volatility components is practically the same as the single compounds; [0103]
  • b) oleic acid in concentration of 1.3% acts as low density low volatile compound and produces an appreciable increase in particle MMAD; [0104]
  • c) the influence of the low volatility component of the MMAD is correlated to its density; oleic acid in concentration of 1.3% produces an increase in MMAD to a definitely less extent than 1.2% of glycerol, which has a higher density; [0105]
  • d) the presence in the formulation of two active materials, the low volatility ingredient and the stabilizer, does not cause any interference between the components. [0106]
  • Oleic acid is another preferred material for a low density low volatility component. [0107]
  • Finally, Table 12 shows that the addition of a low volatility component allows the modulation of the MMAD of an active material formulated as a solution in an HFA 227/ethanol system. [0108]
  • Therefore, the formulations of the invention allow improvement of the delivery characteristics of drugs to the lung by modulating the aerodynamic particle size and size distribution so that the pattern of deposition gives an equivalent clinical effect. [0109]
    TABLE 1
    BDP formulations in HFA 134a and ethanol - Actuator orifice 0.25 mm
    BDP BDP BDP BDP
    10 mg/10 ml 10 mg/10 ml 20 mg/10 ml 20 mg/10 ml
    ethanol ethanol ethanol ethanol
    7.9% 12.9-13.0% 7.9% 13.0%
    Mean emitted 44.7 45.1 84.8 87.6
    dose (μg)
    Fine particle 31.1 24.5 63.1 46.2
    dose (μg)
    MMAD ± GSD 0.8 ± 1.8 0.9 ± 2.0 1.0 ± 1.8 1.0 ± 1.9
    Shot weight 59.0 58.7 59.1 57.6
    (mg)
    Replications 6 2 6 2
  • [0110]
    TABLE 2
    BDP formulations in HFA 134a, ethanol and small amounts of water (up
    to 0.5%) - Actuator orifice 0.33 mm
    BDP BDP BDP BDP
    10 mg/10 ml 10 mg/10 ml 50 mg/10 ml 50 mg/10 ml
    ethanol ethanol ethanol ethanol
    13.7% 13.6% 14.9% 14.9%
    H2O 0.1% H2O 0.5% H2O 0.1% H2O 0.5%
    Mean emitted 43.2 42.9 222.1 215.1
    dose (μg)
    Fine particle 14.9 12.7 67.4 60.2
    dose (μg)
    MMAD (μm) ± 1.0 ± 2.2 1.0 ± 2.1 1.8 ± 2.2 1.7 ± 2.2
    GSD
    Shot weight 58.1 58.0 59.0 57.5
    (mg)
    Replications 6 6 6 6
  • [0111]
    TABLE 3
    Comparison of standard CFC ipratropium bromide formulation (4 mg/
    10 ml IPBr) and HFA 134a/ethanol-ipratropium bromide solution without
    and in presence of increasing amount of glycerol
    HFA 134a/
    CFC- ethanol
    Formulations IPBr 25% - IPBr** HFA 134a-IPBr*
    Glycerol 0 0 0.5 1.0
    content (%)
    Mean 18.8 17.1 16.1 18.7 18.8
    emitted dose
    (μg)
    Fine particle 6.1 2.6 3.9 6.9 5.6
    dose (μg)
    MMAD 2.8 ± 1.3 ± 2.0 1.2 ± 1.9 ± 2.0 2.5 ± 2.1
    (μm) ± 1.8 1.9
    GSD
    Shot weight 75.4 55.7 58.0 59.0 58.3
    (mg)
    Replications 3 4 6 6 6
  • [0112]
    TABLE 4
    Comparison of BDP formulations in HFA 134a and ethanol in the
    presence of increasing amount of propylene glycol
    Propylene glycol content
    0.0% 1.1% 3.2% 6.8%
    (w/w) (w/w) (w/w) (w/w)
    Mean emitted dose (μg) 41.8 44.0 43.6 44.9
    Fine particle dose (μg) 10.3 9.3 7.3 4.9
    MMAD (μm) ± GSD 1.1 ± 2.3 1.6 ± 3.4 2.9 ± 4.1 4.6 ± 3.9
    Replications 2 6 6 6
  • [0113]
    TABLE 5
    Comparison of BDP formulations in HFA 134a and ethanol in the
    presence of increasing amount of propylene glycol
    Propylene glycol content
    0.0% 0.7% 2.8% 6.3%
    (w/w) (w/w) (w/w) (w/w)
    Mean emitted dose (μg) 209.1 218.4 204.2 242.6
    Fine particle dose (μg) 41.6 41.1 32.1 25.2
    MMAD (μm) ± GSD 1.7 ± 2.3 2.1 ± 2.7 3.3 ± 3.2 4.4 ± 3.8
    Replications 3 3 3 3
  • [0114]
    TABLE 6
    Comparison of BDP formulations in HFA 134a and ethanol in the
    presence of increasing amount of glycerol
    Glycerol content
    0.0% 1.0% 1.3% 1.6%
    (w/w) (w/w) (w/w) (w/w)
    Mean emitted dose (μg) 205.8 218.3 220.8 228.0
    Fine particle dose (μg) 105.9 94.4 100.3 96.6
    MMAD (μm) ± GSD 1.4 ± 1.9 2.4 ± 2.0 2.6 ± 2.0 2.7 ± 2.0
    Replications 6 3 3 2
  • [0115]
    TABLE 7
    Comparison of BDP formulations in HFA 134a and ethanol in the
    presence of increasing amount of glycerol
    Glycerol content
    0.0% 1.0% 1.3% 1.6%
    (w/w) (w/w) (w/w) (w/w)
    Mean emitted dose (μg) 222.1 227.9 228.4 231.7
    Fine particle dose (μg) 67.4 55.9 54.3 50.9
    MMAD (μm) ± GSD 1.8 ± 2.2 2.8 ± 2.2 3.1 ± 2.3 3.1 ± 2.3
    Replications 6 4 3 2
  • [0116]
    TABLE 8
    Comparison of BDP formulations in HFA 134a and ethanol in the
    presence of polyethylene glycol (PEG) 400 or 8000
    PEG 400 PEG 8000
    1.1% (w/w) 1.0% (w/w) 0.0% (w/w)
    Mean emitted dose (μg) 218.9 215.0 222.1
    Fine particle dose (μg) 55.6 55.6 67.4
    MMAD (μm) ± GSD 2.5 ± 2.2 2.5 ± 2.2 1.8 ± 2.2
    Replications 2 1 6
  • [0117]
    TABLE 9
    Comparison of Flunisolide solution formulations in HFA 134a and ethanol
    without and in presence of glycerol
    Menthol Fine Particle Emitted Repli-
    % Glycerol Dose (FPD) Dose cations
    (w/w) % (w/w) (μg) MMAD GSD (μg) (n)
    0   0 76.85 1.8 2.15 217.1 2
    0.4 0.9 77.84 2.9 2.1 221.6 5
  • [0118]
    TABLE 10
    Comparison of Salbutamol base solution formulations in HFA 134a and
    ethanol without and in presence of glycerol
    Emitted Repli-
    Glycerol Oleic Acid dose MMAD cations
    % (w/w) % (w/w) (μg) FPD (μg) (urn) GSD (n)
    0   0.35 85.8 29.1 1.7 2.3 1
    1.3 0.36 92.0 25.2 2.8 2.4 1
  • [0119]
    TABLE 11
    BDP and Salbutamol base combination in solution formulations in HFA 134a and
    ethanol, without and in presence of glycerol, oleic acid and their combination
    Oleic
    Acid BDP Salbutamol Base
    Glycerol % Emitted FPD MMAD Emitted FPD MMAD Actuator exit
    % (w/w) (w/w) dose (μg) (μg) (μm) GSD dose (μg) (μg) (μm) GSD orifice (mm) n
    0 0   208.9 67.8 1.7 2.4 82.5 26.9 1.7 2.2 0.33 2
    0 0.3 212.7 60.6 2.2 2.3 84.8 24.0 2.0 2.6 0.33 2
    0 1.3 212.5 58.5 2.4 2.2 85.9 23.9 2.4 2.1 0.30 1
      1.2 0.3 210.8 63.3 2.9 2.1 85.3 25.1 3.0 2.0 0.30 1
  • [0120]
    TABLE 12
    BDP 50 mg/10 ml formulations in HFA 227
    and ethanol 15.0 ± 0.2% (w/w), with and without
    glycerol as a non volatile additive. HFA 227 fill to 12 ml;
    Actuator orifice 0.33 mm
    HFA 227
    0% (w/w) Glycerol 1.42% (w/w) Glycerol
    FPD (μg) 62.1 43.5
    MMAD (μm) 2.2 4.1
    GSD 2.6 2.4
    Mean emitted dose 221.25 230.5
    (μg)
    Replications 2 2

Claims (23)

1. A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
2. A composition according to
claim 1
, wherein the low volatility component has a vapour pressure at 25° C. not more than 0.1 kPa.
3. A composition according to
claim 2
, wherein the low volatility component has a vapour pressure at 25° C. not more than 0.05 kPa.
4. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25° C. not less than 3 kPa.
5. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25° C. not less than 5 kPa.
6. A composition according to any preceding claim, wherein the cosolvent is an alcohol.
7. A composition according to any preceding claim, wherein the low volatility component includes a glycol.
8. A composition according to any preceding claim, wherein the low volatility component includes oleic acid.
9. A composition according to any preceding claim, wherein the propellant includes one or more HFAs selected from the group comprising HFA 134a and HFA 227.
10. A composition according to any preceding claim, wherein the composition includes not more than 20% by weight of the low volatility component.
11. A composition according to any preceding claim, wherein the composition includes at least 0.2% by weight of the low volatility component.
12. A composition according to any preceding claim, the composition being such that, on actuation of the aerosol inhaler in use, the MMAD of the aerosol particles is not less than 2 μm.
13. A composition according to any preceding claim, wherein the composition is in the form of a solution.
14. Use of a low volatility component in a composition for an aerosol inhaler, the composition comprising an active material, a propellant containing hydrofluoro alkane (HFA) and a cosolvent, to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
15. Use of a low volatility component according to
claim 14
to give a MMAD of the aerosol particles of not less than 2 μm.
16. Use of a low volatility component according to
claim 14
or
claim 15
, wherein the low volatility component has a vapour pressure at 25° C. not more than 0.1 kPa.
17. Use of a low volatility component according to any of
claims 14
to
16
, the composition being as claimed in any of
claims 1
to
13
.
18. An aerosol inhaler containing a composition, the composition being as claimed in any of
claims 1
to
13
.
19. Method of filling an aerosol inhaler with a composition, the method comprising filling the following components into the inhaler
(a) one or more active materials,
(b) one or more low volatility components,
(c) one or more cosolvents
followed by the addition of a propellant containing a hydrofluoroalkane (HFA).
20. A method according to
claim 19
, the composition being as claimed in any of
claims 1
to
13
.
21. Aerosol particles emitted from an aerosol inhaler containing a composition, the composition comprising an active component, a propellant containing a hydrofluoro alkane (HFA), a cosolvent and a low volatility component, wherein the mass median aerodynamic diameter (MMAD) of the aerosol particles is not less than 2 μm.
22. Aerosol particles according to
claim 21
, wherein the MMAD of the particles is not less than 2.5 μm.
23. Aerosol particles according to
claim 21
or
claim 22
, wherein the composition is according to any of
claims 1
to
13
.
US09/796,607 1997-06-13 2001-03-02 Pharmaceutical aerosol composition Abandoned US20010031244A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9712434A GB2326334A (en) 1997-06-13 1997-06-13 Pharmaceutical aerosol compositions
GB9712434.1 1997-06-13
US14766999A true 1999-02-24 1999-02-24
US09/796,607 US20010031244A1 (en) 1997-06-13 2001-03-02 Pharmaceutical aerosol composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/796,607 US20010031244A1 (en) 1997-06-13 2001-03-02 Pharmaceutical aerosol composition
US10/435,032 US7601336B2 (en) 1997-06-13 2003-05-12 Pharmaceutical aerosol composition
US10/435,354 US20030190287A1 (en) 1997-06-13 2003-05-12 Pharaceutical aerosol composition
US10/612,067 US20040062720A1 (en) 1997-06-13 2003-07-03 Pharmaceutical aerosol composition
US12/547,534 US8420058B2 (en) 1997-06-13 2009-08-26 Pharmaceutical aerosol composition

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09147669 Continuation
PCT/EP1998/003533 Continuation WO1998056349A1 (en) 1997-06-13 1998-06-10 Pharmaceutical aerosol composition
US14766999A Continuation 1999-02-24 1999-02-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/435,032 Continuation US7601336B2 (en) 1997-06-13 2003-05-12 Pharmaceutical aerosol composition
US10/435,354 Continuation US20030190287A1 (en) 1997-06-13 2003-05-12 Pharaceutical aerosol composition

Publications (1)

Publication Number Publication Date
US20010031244A1 true US20010031244A1 (en) 2001-10-18

Family

ID=26311726

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/796,607 Abandoned US20010031244A1 (en) 1997-06-13 2001-03-02 Pharmaceutical aerosol composition
US10/435,032 Active 2020-03-20 US7601336B2 (en) 1997-06-13 2003-05-12 Pharmaceutical aerosol composition
US10/435,354 Abandoned US20030190287A1 (en) 1997-06-13 2003-05-12 Pharaceutical aerosol composition
US10/612,067 Abandoned US20040062720A1 (en) 1997-06-13 2003-07-03 Pharmaceutical aerosol composition
US12/547,534 Expired - Lifetime US8420058B2 (en) 1997-06-13 2009-08-26 Pharmaceutical aerosol composition

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/435,032 Active 2020-03-20 US7601336B2 (en) 1997-06-13 2003-05-12 Pharmaceutical aerosol composition
US10/435,354 Abandoned US20030190287A1 (en) 1997-06-13 2003-05-12 Pharaceutical aerosol composition
US10/612,067 Abandoned US20040062720A1 (en) 1997-06-13 2003-07-03 Pharmaceutical aerosol composition
US12/547,534 Expired - Lifetime US8420058B2 (en) 1997-06-13 2009-08-26 Pharmaceutical aerosol composition

Country Status (1)

Country Link
US (5) US20010031244A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040047809A1 (en) * 2000-05-22 2004-03-11 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20040184994A1 (en) * 2003-03-20 2004-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20050123484A1 (en) * 2003-10-02 2005-06-09 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US6967017B1 (en) 1999-07-23 2005-11-22 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20070106604A1 (en) * 2000-01-28 2007-05-10 Fundamo (Proprietary) Limited System for conducting commercial transactions
EP1915985A1 (en) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20090232743A1 (en) * 2008-02-14 2009-09-17 Collegium Pharmaceutical, Inc. Foamable Microemulsion Compositions for Topical Administration
US20150071969A1 (en) * 2002-12-10 2015-03-12 Sunovion Pharmaceuticals Inc. Levalbuterol salt

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulations containing an anticholinergic drug for chronic obstructive pulmonary disease trattamentodella.
EP1340503A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
CA2754691A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2011066107A1 (en) 2009-11-24 2011-06-03 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
WO2011084316A2 (en) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
DK2536412T3 (en) * 2010-02-16 2015-01-19 Teva Branded Pharmaceutical Prod R & D Inc An inhalable PHARMACEUTICAL COMPOSITION
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812417A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
CN103228273B (en) 2010-09-29 2017-04-05 普马特里克斯营业公司 Monovalent metal cations dry inhalation powder
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-chloro-n- (n- (4- (4- (2- (hexyl (2,3,4,5,6-pentahydroxyhexyl) amino) ethoxy) phenyl) butyl) carbamimidoyl) pyrazine -2-carboxamide
TR201809148T4 (en) 2012-05-29 2018-07-23 Parion Sciences Inc Dry eye and other sodium channel blockers for the treatment of mucosal diseases with dendrimer-like activity amino acids.
ES2674665T3 (en) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compounds 3,5-diamino-6-chloro-N- (N- (4-phenylbutyl) carbamimidoyl) pyrazine-2-carboxamide
CN108658876A (en) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
LT2931713T (en) 2012-12-17 2017-02-10 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
JP2017506252A (en) 2014-02-20 2017-03-02 オティトピック インコーポレイテッド Dry powder formulations for inhalation

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US629093A (en) * 1898-09-08 1899-07-18 Daw W Scalf Separable button.
BE555319A (en) * 1956-03-21 1900-01-01
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (en) 1975-05-27 1981-08-26 Syntex Corp A process for preparing 6-fluiro 11b-21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3-20 crystalline compound dione
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
IT1201087B (en) 1982-04-15 1989-01-27 Gentili Ist Spa pharmacologically active bisphosphonates, process for their preparation and related pharmaceutical compositions
JPH0460990B2 (en) 1983-06-07 1992-09-29 Yamanouchi Pharma Co Ltd
US4499108A (en) 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (en) 1984-06-11 1988-11-10 Sicor Spa Process for the preparation of 16,17-acetals of pregnane derivatives and new compounds obtained
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4584320A (en) 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (en) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh New diphosphonic acid derivatives, processes for their preparation and these compounds containing drug
FR2629716B1 (en) 1988-04-07 1991-07-19 Sanofi Sa A pharmaceutical composition for oral administration based on a diphosphonic acid derivative
US5248493A (en) 1988-08-27 1993-09-28 Fisons Plc Pharmaceutical composition
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5227506A (en) 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
JP2769925B2 (en) * 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー Aerosol formulations comprising beclomethasone 17,21 dipropionate
WO1992011236A1 (en) 1990-12-19 1992-07-09 Smithkline Beecham Corporation Aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0585379B1 (en) 1991-05-21 1998-09-30 Abbott Laboratories Aerosol inhalation device
AU653634B2 (en) * 1991-08-29 1994-10-06 Broncho-Air Medizintechnik Ag Medical appliance for inhaling metered aerosols
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
BR9206797A (en) 1991-11-22 1995-10-31 Procter & Gamble Pharma Compositions with delayed release of risedronate
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
SK74594A3 (en) 1991-12-17 1995-01-05 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
DK1086688T3 (en) 1991-12-18 2004-08-16 Minnesota Mining & Mfg Aerosol formulations for suspensions
DE4230876A1 (en) * 1992-03-17 1993-09-23 Asta Medica Ag Aerosols of using polyoxyethylene glyceryl oleates
JP4481368B2 (en) 1992-06-30 2010-06-16 味の素株式会社 Phosphonates of applications for the for the treatment of osteoporosis
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3009924B2 (en) 1992-12-09 2000-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Stabilization medical aerosols solution formulation
SE9203743D0 (en) * 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014490A1 (en) 1992-12-23 1994-07-07 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
JPH08507792A (en) 1993-03-17 1996-08-20 ミネソタ マイニング アンド マニュファクチャリング カンパニー Diol - aerosol formulation comprising a dispersing aid which is derived from a diacid
FR2703590B1 (en) 1993-04-05 1995-06-30 Sanofi Elf Use of bisphosphonic acid derivatives for the preparation of medicaments intended to promote bone repair.
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
AU680967B2 (en) 1993-12-20 1997-08-14 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
US5646134A (en) 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5780455A (en) 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
MY131733A (en) 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh A stable aqueous budesonide solution
PL321835A1 (en) 1995-02-17 1997-12-22 Merck & Co Inc Method of reducing the risk of non-vertebral bone fracture
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
PL180880B1 (en) 1995-04-14 2001-04-30 Glaxo Wellcome Inc. Beclomethasone inhaler with dosis metering feature
BR9604977A (en) 1995-04-14 1998-06-09 Glaxo Wellcome Inc metered dose inhaler a metered dose inhaler system and use thereof
DE69636757T2 (en) 1995-04-14 2007-10-11 Smithkline Beecham Corp. Metered dose inhaler for Fluticasonepropionat
HU219900B (en) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Metered dose inhaler
IL118422D0 (en) 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
US5616571A (en) 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
AU3453897A (en) 1996-07-08 1998-02-02 Rhone-Poulenc Rorer Limited Medicinal cyclosporin-a aerosol solution formulation
WO1998003533A1 (en) 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US5773429A (en) 1996-12-11 1998-06-30 Fuisz Technologies Ltd. Drug combination for treating calcium loss
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (en) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation
PL200941B1 (en) 1998-11-13 2009-02-27 Jagotec Ag Dry powder for inhalation
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa pressurized meter dose inhaler.
IT1303788B1 (en) 1998-11-25 2001-02-23 Chiesi Farma Spa Aerosol formulations of medicines.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (en) * 2000-01-07 2003-07-15 Chiesi Farma Spa A device for the administration of pressurized metered dose aerosol inpropellenti hydrofluoroalkanes.
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulations containing an anticholinergic drug for chronic obstructive pulmonary disease trattamentodella.
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulations containing a glucocorticosteroid drug iltrattamento of bronchopulmonary diseases.
HU230804B1 (en) 2000-05-22 2018-06-28 Chiesi Farm Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
BR0308274A (en) 2002-03-01 2004-12-28 Chiesi Farma Spa Superfine formoterol Formulation
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
JP2006196065A (en) * 2005-01-12 2006-07-27 Fuji Photo Film Co Ltd Servo writer

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20090311196A1 (en) * 1997-06-13 2009-12-17 Chiesi Farmaceutici S.P.A Pharmaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US7601336B2 (en) 1997-06-13 2009-10-13 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US8420058B2 (en) 1997-06-13 2013-04-16 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040096399A1 (en) * 1998-11-25 2004-05-20 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US7740463B2 (en) 1998-11-25 2010-06-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20050220717A1 (en) * 1999-06-18 2005-10-06 3M Innovative Properties Company Steroid solution aerosol products with enhanced chemical stability
US6967017B1 (en) 1999-07-23 2005-11-22 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20070106604A1 (en) * 2000-01-28 2007-05-10 Fundamo (Proprietary) Limited System for conducting commercial transactions
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US7018618B2 (en) 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20040047809A1 (en) * 2000-05-22 2004-03-11 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20100098642A1 (en) * 2001-07-02 2010-04-22 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7939502B2 (en) 2001-07-02 2011-05-10 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US8168598B2 (en) 2001-07-02 2012-05-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20110212912A1 (en) * 2001-07-02 2011-09-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7696178B2 (en) 2001-07-02 2010-04-13 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US8313732B2 (en) 2002-03-01 2012-11-20 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20110061651A1 (en) * 2002-03-01 2011-03-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US8088362B2 (en) 2002-10-23 2012-01-03 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20150071969A1 (en) * 2002-12-10 2015-03-12 Sunovion Pharmaceuticals Inc. Levalbuterol salt
US20160368858A1 (en) * 2002-12-10 2016-12-22 Sunovion Pharmaceuticals Inc. Levalbuterol salt
EP1915985A1 (en) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
US7914770B2 (en) 2003-03-20 2011-03-29 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20040184994A1 (en) * 2003-03-20 2004-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20050123484A1 (en) * 2003-10-02 2005-06-09 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US8357352B2 (en) 2004-07-02 2013-01-22 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US8518377B2 (en) 2006-04-11 2013-08-27 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US20090232743A1 (en) * 2008-02-14 2009-09-17 Collegium Pharmaceutical, Inc. Foamable Microemulsion Compositions for Topical Administration

Also Published As

Publication number Publication date
US20030190287A1 (en) 2003-10-09
US7601336B2 (en) 2009-10-13
US20030206870A1 (en) 2003-11-06
US8420058B2 (en) 2013-04-16
US20090311196A1 (en) 2009-12-17
US20040062720A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
US6582677B1 (en) Propellant compositions of a particulate medicament that are free of solvents
US5683676A (en) Canister containing aerosol formulations containing P134a and particulate medicaments
CA2455115C (en) Pharmaceutical aerosol formulation
EP1287820B1 (en) Aerosol compositions
JP3497161B2 (en) Their use in new propellant mixture and pharmaceutical preparations
RU2327450C2 (en) Pharmaceutical products and compositions containig specific anticholinergic agents, antagonists of beta-2 and corticosteroids
EP0372777B1 (en) Medicinal aerosol formulations
US5688782A (en) Medicaments for treating respiratory disorders
AU2002313828B2 (en) Pharmaceutical compositions for the treatment of asthma
EP1092430B1 (en) Non-chlorofluorocarbon aerosol formulations
US5744123A (en) Aerosol formulations containing P134a and particulate medicaments
EP0755247B1 (en) Hydrofluorocarbon propellant containing medicinal aerosols
JP3497162B2 (en) Their use in new propellant and pharmaceutical formulation
DE69929358T2 (en) Pressurized metered dose inhalers
EP0587790B1 (en) Non-chlorofluorocarbon aerosol formulations
US6932962B1 (en) Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6585958B1 (en) Medicinal aerosol formulations
ES2249424T3 (en) Formulations containing an anticholinergic drug for the treatment of Chronic Obstructive Bronchopulmonary.
US6333023B1 (en) Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
RU2586297C2 (en) Compositions, methods and systems for respiratory delivery of two or more active agents
RU2294737C2 (en) Medicinal aerosol compositions
CA2280099C (en) Medical aerosol formulations
US20100063016A1 (en) Pharmaceutical Combinations
JP4659160B2 (en) Propellant novel aqueous pharmaceutical formulations for the free aerosol preparation
AU649702B2 (en) Aerosol drug formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIESI FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEWIS, DAVID;GANDERTON, DAVIS;MEAKIN, BRIAN;AND OTHERS;REEL/FRAME:014030/0576

Effective date: 19990210